Nicholson Nur's Form 4 filing
Apellis Pharmaceuticals, Inc. (APLS) · filed Jan 21, 2025
- Accession no.
- 0001127602-25-001625
- Filed
- Jan 21, 2025
- Trade date
- Jan 17-21, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $64.3K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nicholson NurCIK 0001827317 | Officer (Chief Technical Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 17, 2025 | Common Stock | SSaleDisposed | −2,145 | $29.96 | −$64,264.2 | 52,011 | Direct | |
| Jan 21, 2025 | Common Stock | AGrant or awardAcquired | +36,426 | $0.00 | $0 | 88,437 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.